From initial discovery to market-ready product, biotech development is a complex multi-phase process, where strategic partnerships, continuous innovation and careful navigation of regulatory landscapes are crucial for long-term success. Despite this complexity (or perhaps because of it), entrepreneurs and VCs seldom take a step back to consider the full trajectory of this journey. In this article, we’ll explore the typical life cycle of a biotech startup, examining the key milestones and hurdles encountered along the way.
Like two sides of the same coin, industry and academia are each aiming to progress science. On their own, they accomplish great results, but only together can they really drive innovation. One way to reap the fruits from this partnership are endowed chairs. By exchanging resources and independence for publicity and innovative insights, both can contribute to a happier and healthier society.
Sepsis is a serious condition where the body responds improperly to an infection. Every 2.8 seconds, someone dies of sepsis globally, yet no direct therapies exist beyond supportive care. Many clinical trials have investigated the role of Tumor Necrosis Factor (TNF) as a potential therapeutic target, but anti-TNF therapy has not proven to be a breakthrough in the sepsis field. Therefore, understanding how TNF triggers this devastating condition could be of help for millions of people worldwide.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
Meeting the needs of a growing global population while addressing the clear demand for a more sustainable food supply is challenging but not impossible. Innovative biotechnological tools are constantly being created, and they are increasingly available on the market. However, the industry is in desperate need of support, as EU legislation can act as more of a hurdle than a facilitator, hindering local advancement. flanders.bio is committed to advocating for the sector and highlights the most pressing challenges in their latest policy paper.
In line with its stellar name, AstriVax Therapeutics is a rising star in Belgian biotech. The company launched in 2022 with €30 million – the largest seed round ever raised by a KU Leuven spin-out – and rapidly became a clinical-stage company, using its plug-and-play platform to fast-track development of vaccines and immunotherapies.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Every start-up team ponders the all-important question: how to convince investors to fund their idea? Currently, the fundraising landscape is particularly challenging for most early-stage biotech ventures. A fortunate few are raising exorbitant rounds, allowing them to advance their products through preclinical development, but many others are struggling to find the funding they require. In this article, we share our investor perspective on what can help companies to stand out from the crowd, given recent advancements in drug development.
Ghent, Belgium, 4 December 2024 - At MEDVIA, we see the future of HealthTech filled with potential – a future powered by the intersection of health and technology. This is where breakthroughs in healthtech, medtech, AI and digital solutions promise to transform care delivery. It’s where patients have a voice, hospitals and caregivers have access to cutting-edge innovations, and technology like AI is making personalized medicine a reality. That future isn’t distant; it’s already here.
From initial discovery to market-ready product, biotech development is a complex multi-phase process, where strategic partnerships, continuous innovation and careful navigation of regulatory landscapes are crucial for long-term success. Despite this complexity (or perhaps because of it), entrepreneurs and VCs seldom take a step back to consider the full trajectory of this journey. In this article, we’ll explore the typical life cycle of a biotech startup, examining the key milestones and hurdles encountered along the way.
Like two sides of the same coin, industry and academia are each aiming to progress science. On their own, they accomplish great results, but only together can they really drive innovation. One way to reap the fruits from this partnership are endowed chairs. By exchanging resources and independence for publicity and innovative insights, both can contribute to a happier and healthier society.
Sepsis is a serious condition where the body responds improperly to an infection. Every 2.8 seconds, someone dies of sepsis globally, yet no direct therapies exist beyond supportive care. Many clinical trials have investigated the role of Tumor Necrosis Factor (TNF) as a potential therapeutic target, but anti-TNF therapy has not proven to be a breakthrough in the sepsis field. Therefore, understanding how TNF triggers this devastating condition could be of help for millions of people worldwide.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
Meeting the needs of a growing global population while addressing the clear demand for a more sustainable food supply is challenging but not impossible. Innovative biotechnological tools are constantly being created, and they are increasingly available on the market. However, the industry is in desperate need of support, as EU legislation can act as more of a hurdle than a facilitator, hindering local advancement. flanders.bio is committed to advocating for the sector and highlights the most pressing challenges in their latest policy paper.
In line with its stellar name, AstriVax Therapeutics is a rising star in Belgian biotech. The company launched in 2022 with €30 million – the largest seed round ever raised by a KU Leuven spin-out – and rapidly became a clinical-stage company, using its plug-and-play platform to fast-track development of vaccines and immunotherapies.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Every start-up team ponders the all-important question: how to convince investors to fund their idea? Currently, the fundraising landscape is particularly challenging for most early-stage biotech ventures. A fortunate few are raising exorbitant rounds, allowing them to advance their products through preclinical development, but many others are struggling to find the funding they require. In this article, we share our investor perspective on what can help companies to stand out from the crowd, given recent advancements in drug development.
Ghent, Belgium, 4 December 2024 - At MEDVIA, we see the future of HealthTech filled with potential – a future powered by the intersection of health and technology. This is where breakthroughs in healthtech, medtech, AI and digital solutions promise to transform care delivery. It’s where patients have a voice, hospitals and caregivers have access to cutting-edge innovations, and technology like AI is making personalized medicine a reality. That future isn’t distant; it’s already here.